SEC Loosens Revenue-Recognition Rules for Vaccine Stockpile Participants
ePT--the Electronic Newsletter of Pharmaceutical Technology
SEC Loosens Revenue-Recognition Rules for Vaccine Stockpile Participants
The US Securities and Exchange Commission (Washington, DC, www.sec.gov) this week issued an interpretive guidance that allows vaccine manufacturers participating in government stockpile programs to recognize revenue at the time the vaccines are added to the stockpile. According to the interpretation, such immediate-revenue recognition applies “even if certain criteria that normally apply to ‘bill and hold’ arrangements are not met.”
Vaccine manufacturers would still be required to meet all other applicable revenue-recognition criteria and to provide “sufficient disclosures for a clear understanding by investors of transactions, the related accounting, and the effect of the alternative accounting method.”
The SEC issued the guidance in response to suggestions and some concerns, reportedly by members of Congress, that the current rules could cause some vaccine manufacturers to decline participation in federal vaccine stockpile programs (see Solomon and Burns,
The Wall Street Journal,
Dec. 6, 2005, p. D5,
www.wsj.com
).>
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
